Exocrine Pancreatic Insufficiency Market Size to Grow Steadily, Projected to Hit $3.58 Billion by 2029 at 6.7% CAGR

 The Business Research Company’s report on the Amusement Parks Global Market Report 2025 Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.

 
 #What are the primary drivers fueling the growth of the exocrine pancreatic insufficiency market in recent years?#
 The rise in chronic diseases is expected to propel the growth of the exocrine pancreatic insufficiency market going forward. Chronic diseases are long-term medical conditions that persist over an extended period, typically three months or more. The prolonged presence of the underlying disease can also increase the likelihood of developing secondary complications like exocrine pancreatic insufficiency, which fuels the better management of chronic conditions through medical interventions and therapies and can lead to longer life spans for individuals with these conditions. For instance, In September 2023, the World Health Organization, a specialized agency of the United Nations based in Switzerland, reported that 41 million deaths occur annually, with 74% attributed to non-communicable diseases (NCDs) or chronic diseases worldwide. Therefore, the rise in chronic diseases will drive the growth of the exocrine pancreatic insufficiency market.
 
 Exocrine Pancreatic Insufficiency Market Driver: Escalating Diabetes Epidemic Fuels Expansion Of The Exocrine Pancreatic Insufficiency Market
 
 Rising cases of diabetes are expected to propel the growth of the exocrine pancreatic insufficiency market going forward. Diabetes is a chronic (long-lasting) health condition when the body does not produce sufficient insulin or misuses it. Excessive blood sugar accumulates in the bloodstream because there is insufficient insulin or when cells cease reacting to insulin. Pancreatic enzyme replacement treatment (PERT) is required to produce enough digestive enzymes for exocrine pancreatic insufficiency (EPI), which helps to maintain the body’s insulin level. For instance, in June 2023, according to a report published by the Institute for Health Metrics and Evaluation, a US-based independent global research center for health statistics and impact evaluation, the number of global diabetes cases is expected to be 1.3 billion in 2050, from 529 million in 2022. Therefore, the rising cases of diabetes will drive the growth of the exocrine pancreatic insufficiency market.
 
 #Access Your Free Sample of the Global Amusement Parks Global Market Report 2025 Market Report — Get Insights Now!#
 https://www.thebusinessresearchcompany.com/sample.aspx?id=13107&type=smp
 
 #What is the projected market size of the exocrine pancreatic insufficiency industry, and how is it expected to grow?#
 The exocrine pancreatic insufficiency market size has grown strongly in recent years. It will grow from $2.59 billion in 2024 to $2.76 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to increased awareness and diagnosis, growing prevalence of digestive disorders, aging population, and pancreatic function decline, rise in gastrointestinal surgeries.
 
 The exocrine pancreatic insufficiency market size is expected to see strong growth in the next few years. It will grow to $3.58 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to continued increase in awareness and screening, expanding geriatric population, rising incidence of chronic diseases, improvements in patient access to healthcare, research and development in digestive health. Major trends in the forecast period include telehealth and digital health solutions, collaborative research initiatives, focus on pediatric epi, regulatory advances and fast-track designations, market expansion in emerging economies, advancements in healthcare infrastructure.
 
 #Gain Exclusive Market Insights — Customize Your Research Report Today For Fast Delivery!#
 https://www.thebusinessresearchcompany.com/customise?id=13107&type=smp
 
 #Who are the key players driving competition in the exocrine pancreatic insufficiency market?#
 Major companies operating in the exocrine pancreatic insufficiency market report are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca PLC, Medtronic PLC, Eli Lilly and Company, Gilead Sciences Inc., Nestle Health Science S.A., Allergan PLC, Chiesi Farmaceutici S.p.A., Wockhardt Ltd., Amryt Pharma PLC, Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, Aimmune Therapeutics Inc., Digestive Care Inc., Enzymedica Inc., Vivus Inc., Alcresta Therapeutics Inc., Cilian AG, Perseo Pharma AG, Enzyme Development Corporation, First Wave BioPharma Inc., Synspira Therapeutics
 
 #What key trends are expected to drive the executive coaching certification market during the forecast period?#
 Major companies operating in the exocrine pancreatic insufficiency market are focusing on creating patient advocacy groups such as comprehensive nutritional guidance to provide comprehensive nutritional guidance and support. These initiatives aim to improve awareness, education, and management of the condition among affected individuals. Comprehensive nutritional guidance is a holistic approach that tailors dietary recommendations based on individual needs, health conditions, and lifestyle. It emphasizes education, meal planning, and sustainable practices to promote overall well-being. For instance, in June 2024, Nestlé Health Science, a Switzerland-based nutrition company, launched a GLP-1 nutrition support platform. Nestlé Health Science’s GLP-1 nutrition support platform offers tailored nutritional resources and expert guidance for individuals using GLP-1 medications, focusing on muscle preservation, gut health, and overall wellness. Its purpose is to empower users in their weight management journey by addressing unique dietary needs and fostering community support.
 
 #Which key geographies are driving the growth of the exocrine pancreatic insufficiency market?#
 North America was the largest region in the exocrine pancreatic insufficiency market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the exocrine pancreatic insufficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
 
 #Order Your Report Now For Swift Delivery#
 https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-global-market-report
 
 #What are the key segments driving growth in the exocrine pancreatic insufficiency market?#
 The exocrine pancreatic insufficiency market covered in this report is segmented –
 
 1) By Treatment: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Other Treatments
 2) By Diagnosis: Imaging Tests, Computed Tomography (CT) Scan, Abdominal Ultrasound, Secretin Pancreatic Function Test, Fecal Fat Test, Fecal Elastase Test (FE-1), Other Types
 3) By Symptoms: Abdominal Pain, Constipation, Diarrhea, Fatty Stools, Weight Loss, Other Symptoms
 4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
 5) By End Users: Hospitals, Specialty Clinics, Homecare
 
 Subsegments:
 1) By Nutritional Management: Dietary Modifications, Nutritional Supplements
 2) By Pancreatic Enzyme Replacement Therapy (PERT): Enteric-Coated Capsules, Non-Enteric-Coated Capsules, Powder Formulations
 3) By Other Treatments: Medications, Surgical Interventions, Supportive Therapies
 
 #Purchase The Exclusive Report Now To Unlock Valuable Market Insights:#
 https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13107
 
 #How is the exocrine pancreatic insufficiency market defined, and what are its core characteristics?#
 Exocrine pancreatic insufficiency (EPI) is a medical condition characterized by the pancreas’s insufficient production or release of digestive enzymes into the small intestine. These enzymes are essential for the digestion and absorption of nutrients from food. Exocrine pancreatic insufficiency can lead to malnutrition and digestive symptoms, including diarrhea, abdominal pain, bloating, and weight loss.
 
 #About The Business Research Company:#
 
 With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
 
 Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
 
 #Contact Us:#
 
 The Business Research Company
 
 https://thebusinessresearchcompany.com/
 
 Europe: +44 207 1930 708
 
 Asia: +91 88972 63534
 
 Americas: +1 315 623 0293
 
 Email: info@tbrc.info
 
 
 #Follow Us On:#
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company